Clinical trials: Restless Legs Syndrome
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
The primary objective of this study is to investigate the effects on RLS symptoms and sleep disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks, compared to placebo, in the treatment of patients…
- Trial name
- NCT00349531
- Testing
- Pramipexole
- Where
- 49 sites in Denmark, Finland and 7 more
- Volunteers
- 369 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome, Depression
Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances
The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to 0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and depressive symptoms, after 12 weeks of treatment
- Trial name
- NCT00356096
- Testing
- pramipexole
- Where
- 54 sites in Finland, France and 7 more
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in…
- Trial name
- NCT00367822
- Testing
- Lisuride, Ropinirole
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Axxonis Pharma AG
Restless Legs Syndrome
The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome
The purpose of this study is to assess the efficacy and tolerability of single doses of aplindore compared to placebo in RLS. Patients will be required to spend 5-8 nights in a sleep laboratory.
- Trial name
- NCT00626418
- Testing
- Aplindore
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Ligand Pharmaceuticals
Restless Legs Syndrome
A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS
The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS.
- Trial name
- NCT00627003
- Testing
- Cabergoline
- Volunteers
- 43 people
- Sponsor
- Pfizer
Restless Legs Syndrome
Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome
This is a clinical trial to be conducted at multiple sites in the USA. Patients diagnosed with moderate to severe Restless Legs Syndrome will be randomly allocated to one of 5 treatment arms in the study.
- Trial name
- NCT00834327
- Where
- 24 sites in United States
- Volunteers
- 230 people
- Sponsor
- Neurogen Corporation
Restless Legs Syndrome
Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs
The proposed study is a Cross-sectional epidemiological study, performed in 330 primary care practices in Germany. The study will be conducted on a fixed day in November 2007.
- Trial name
- NCT00557258
- Where
- 251 sites in Germany
- Volunteers
- 14,956 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS
The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.
- Trial name
- NCT00625547
- Testing
- cabergoline, levodopa
- Where
- 50 sites in Austria, Germany and 2 more
- Volunteers
- 361 people
- Sponsor
- Pfizer